This research demonstrates how Chlamydia trachomatis enhances neutrophil lifespan through RIP3 and Mcl-1, indicating complex immune evasion mechanisms.
Chlamydia trachomatis , an obligate intracellular pathogen, manipulates host cells to evade immune detection, contributing to sexually transmitted diseases with severe complications. Neutrophils, short-lived effector cells, form the first line of innate immune defense against infection. Here, we demonstrate that Chlamydia infection extends the lifespan of human neutrophils, creating a cellular niche for its own survival. Lifespan extension involves the neutrophil PI3K/Akt- and the NF-κB signaling pathways. In addition, infection activates the necroptotic effector receptor-interacting protein kinase 3 (RIP3) without inducing cell death. Instead, RIP3 stabilizes the anti-apoptotic protein Mcl-1, enhancing neutrophil survival. This extended survival of neutrophils correlates with an increased number of infectious Chlamydia particles. Mcl-1 plays a critical role in neutrophil survival, lifespan extension, and Chlamydia survival. Notably, inhibiting RIP3 reduces Mcl-1 levels in neutrophils without affecting their survival. Under these conditions, however, Chlamydia load increases, and the dependence on Mcl-1 is bypassed. Our data reveal a new role for necroptosis in neutrophil defense against intracellular Chlamydia , highlighting a complex interplay between RIP3 and Mcl-1 that extends neutrophil lifespan and enhances Chlamydia survival within these hostile cells. IMPORTANCE This study reveals how Chlamydia trachomatis , a common sexually transmitted bacterium, manipulates the body’s first immune responders, the neutrophils, to aid its own survival. Normally short-lived, neutrophils live longer when infected by Chlamydia , creating a safe environment for the bacteria. This lifespan extension is driven by specific cell survival signals and a protein called RIP3, which surprisingly does not cause cell death here, but helps stabilize another protein, Mcl-1, that keeps neutrophils alive. Blocking RIP3 reduces Mcl-1, but Chlamydia still manages to survive, suggesting it can adapt to changes in the host environment. These findings uncover a new layer of complexity in how our immune system interacts with infections and could inform future strategies for treating Chlamydia and similar infections.
No takes yet. Share an insight, caveat, or question.
Koch et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: